Over the Counter Approaches That Support Patients Taking Sitagliptin

Patients with type 2 diabetes who take sitagliptin for glucose management often look for non-prescription supplements and dietary modifications that complement their pharmaceutical treatment. Several OTC options are well-supported for metabolic benefit alongside DPP-4 inhibitor therapy, and understanding compatibility helps patients make beneficial choices without interfering with their medication. Dietary fiber supplementation is one of the most evidence-backed non-prescription complements to diabetes pharmacotherapy. Fiber slows gastric emptying and the absorption of carbohydrates into the bloodstream, which reduces post-meal glucose spikes. When taken before carbohydrate-containing meals, soluble fiber supplements such as psyllium husk work with sitagliptin's incretin-enhancing mechanism by moderating the glucose load that triggers insulin response. Consistent fiber supplementation also improves overall glycemic control markers over time. Berberine, a compound derived from several traditional plant sources, has been studied for glucose-lowering activity through AMP kinase activation. Low-level clinical evidence supports a modest reduction in fasting glucose and hemoglobin A1C with consistent berberine supplementation in type 2 diabetes. Patients considering berberine should inform their providers because its additive glucose-lowering effect with sitagliptin may affect their overall management plan and monitoring frequency. Alpha-lipoic acid is an antioxidant supplement with some evidence for insulin sensitivity improvement and modest glucose-lowering activity. It is generally considered safe alongside sitagliptin at standard supplement doses. Patients with diabetes-associated neuropathy sometimes use alpha-lipoic acid for its neurological support properties in addition to metabolic benefits. Chromium supplementation at standard doses is generally safe alongside sitagliptin. Some patients report modest glycemic improvement with chromium picolinate, and it does not interact with the DPP-4 inhibitor mechanism directly. Magnesium status is relevant for patients with type 2 diabetes because magnesium deficiency is associated with worsened insulin resistance. Standard magnesium supplementation is safe alongside sitagliptin for patients with normal kidney function. Patients with reduced kidney function should discuss magnesium supplementation with their provider due to reduced magnesium clearance. Patients taking sitagliptin alongside a sulfonylurea should be cautious with any supplement that also lowers glucose because additive hypoglycemia risk increases. This consideration is most relevant for berberine and other glucose-active supplements when the full oral diabetes regimen is already lowering blood sugar meaningfully. For patients who want guidance on beneficial non-prescription additions to their diabetes management, reviewing over the counter options combined with januvia-sitagliptin therapy provides practical and personalized context. For patients seeking a broader view of lifestyle and supplemental support across the diabetes medication category, the resources at diabetes medication and management guides offer comprehensive support.

New drug may be best weapon against deadly superbug seen across U.S.

By www.chicagotribune.com

A newly approved drug may help in the battle against Clostridium difficile — a potentially fatal "superbug" gut infection that has become a scourge in U.S. hospitals.

In two clinical trials, researchers found that the drug, called bezlotoxumab (Zinplava), cut the risk of a recurrent C. difficile infection by almost 40 percent.

That's important, because the gut infection commonly comes back after treatment with antibiotics — around 20 percent of the time, according to the U.S. Centers for Disease Control and Prevention.

RELATED: TRENDING LIFE & STYLE NEWS THIS HOUR

The infection can also make people seriously ill, with symptoms ranging from diarrhea to life-threatening inflammation of the colon, the CDC says.

Zinplava has already been approved by the U.S. Food and Drug Administration, and it should be available early this year, according to Merck, the drug's maker.

That approval was based on the findings of two Merck-funded trials, recently published in the New England Journal of Medicine.

The drug "will give us another tool in the toolbox" for fighting C. difficile infections, said Dr. Johan Bakken, former president of the Infectious Diseases Society of America.

And additional weapons are welcome, he said, given the scope the problem.

C. difficile sickened almost half a million Americans in 2011, according to the most recent numbers from the CDC. An estimated 29,000 of those patients died within a month.

Most infections happen in the hospital, the CDC says.

In fact, C. difficile has become the most common hospital-acquired infection nationwide, Bakken pointed out.

The bacteria can contaminate hospital surfaces and equipment, and be transmitted to patients. That's a particular threat when patients are on powerful antibiotics to treat an infection: The drugs kill not only harmful bacteria, but also the "good" bacteria that normally dwell in the gut and crowd out the bad ones.

"The antibiotics hit the innocent bystanders, and that allows C. difficile to get a stronghold," said Bakken, who wasn't involved in the Zinplava trials.

To treat C. difficile, doctors use more antibiotics, which actually do a good job of killing the bug. The problem, Bakken explained, is that C. difficile produces spores that can survive the onslaught.

Once the antibiotics are stopped, those spores can spring to life again and churn out illness-causing toxins.

Zinplava is not an antibiotic. It's a lab-generated "monoclonal" antibody designed to neutralize one of the C. difficile toxins — toxin B — and can keep it from damaging the colon lining, Bakken explained.

"But it's not meant to be used alone," he stressed. Patients receive standard antibiotics, plus an IV infusion of Zinplava.

The two trials involved over 2,600 adults who all received antibiotics for a first-time or recurrent C. difficile infection. Some were randomly assigned to receive a Zinplava infusion, while the rest received a saline infusion that served as a placebo.

Over 12 weeks, 16 percent to 17 percent of Zinplava patients suffered a recurrent infection. That compared with 26 percent to 28 percent of placebo patients, the findings showed.

The drug's main side effects included fever, nausea and diarrhea — which affected between 5 percent and 7 percent of patients. According to Merck, there is also a concern about worsening heart failure in people who already have the disease.

The drug is not for everyone with C. difficile infection, Bakken said.

It's officially approved for people at "high risk" of a recurrence.

Plus, Bakken noted, the drug is sure to be expensive — as monoclonal antibody drugs always are.

Dr. Mark Wilcox, the lead researcher on the trials, agreed that doctors will have to give the drug based on patients' personal odds of a recurrence.

According to Wilcox, some high-risk patients include those who are age 65 or older, have a compromised immune system or have a severe C. difficile infection.

"Bezlotoxumab was more effective in such patients," said Wilcox, a professor of medical microbiology at the University of Leeds in England. "So doctors should consider adding it to standard-of-care antibiotics according to these risk factors."

The drug is not the final answer, however.

"The recurrence rates were in the teens rather than the 20s," Bakken pointed out.

He said researchers are working on other ways to protect vulnerable patients from C. difficile — including vaccines. They also want to figure out which "key organisms" are needed in the gut to ward off the infection, Bakken said.

A study last year hinted that "good" strains of the C. difficile bug, itself, could be beneficial. In that study, patients given antibiotics and a liquid containing non-toxic C. difficile had a lower risk of a repeat infection, versus those who drank a placebo brew.

Source: http://www.chicagotribune.com/lifestyles/health/sc-new-drug-fatal-superbug-gut-infection-health-0201-20170127-story.html

http://antibio.xyz/ifitrim/